

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**



**LISTING OF CLAIMS:**



**1. (canceled).**


**2. (currently amended)** A prodrug of the compound according to claim ~~1~~68.

**3.-67. (canceled).**

**68. (currently amended)** The A compound according to claim 1, which is a compound of either represented by the following formula (I-A), formula (I-B), formula (I-C), formula (I-D) or formula (I-E):







wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) ~~C2-8 alkynyl~~, (4) ~~(3)~~ a halogen atom, (5) ~~(4)~~ trihalomethyl, (6) ~~nitro~~, (7) ~~cyano~~, (8) ~~(5)~~ Cyc1, (9) ~~(6)~~ -OR<sup>6</sup>, (10) ~~SR<sup>7</sup>~~, (11) ~~NR<sup>8</sup>R<sup>9</sup>~~, (12) ~~CONR<sup>10</sup>R<sup>11</sup>~~, (13) ~~NR<sup>12</sup>COR<sup>13</sup>~~, (14) ~~SO<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>~~, (15) ~~NR<sup>16</sup>SO<sub>2</sub>R<sup>17</sup>~~, (16) ~~SO<sub>2</sub>R<sup>18</sup>~~, (17) ~~COR<sup>19</sup>~~, (18) ~~COOR<sup>20</sup>~~, or (19) ~~(7)~~ C1-8 alkyl substituted with -OR<sup>6</sup>, -SR<sup>7</sup>, -NR<sup>8</sup>R<sup>9</sup> or Cyc1;

$R^6$  represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) ~~C2-8 alkynyl~~, (5) ~~(4)~~ Cyc1, (6) ~~(5)~~ methyl substituted with 1 to 3 halogen, or (7) ~~(6)~~ C1-8 alkyl substituted with Cyc1;

$R^7$  to  $R^{16}$  and  $R^{20}$  each independently represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) ~~C2-8 alkynyl~~, or (5) Cyc1;

$R^{17}$ ,  $R^{18}$  and  $R^{19}$  each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) ~~C2-8 alkynyl~~, or (4) Cyc1;

Cyc1 represents a C3-10 monocyclic or bicyclic carbocyclic group or a ~~three to ten membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);~~

G represents a bond,

K and M each independently represents (1) a bond, (2) C1-8 alkylene, or (3) C2-8 alkenylene, or (4) ~~C2-8 alkynylene~~;

J represents a nitrogen atom or a carbon atom;

L represents a bond, or an oxygen atom or a sulfur atom;

~~Ring A, ring B and ring D each independently represents a C3-10 monocyclic or bicyclic carbocyclic group or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);~~

Ring B represents a C3-10 monocyclic or bicyclic carbocyclic group or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring D represents a C3-10 monocyclic carbocyclic group or a three- to ten-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring E represents a C3-7 monocyclic carbocyclic group or a three- to seven-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

p, q, r and s each independently represents 0 or an integer of from 1 to 5,

in which R<sup>1</sup>'s are the same or different when p represents 2 or more; R<sup>2</sup>'s are the same or different when q represents 2 or more; R<sup>3</sup>'s are the same or different when r represents 2 or more; and R<sup>4</sup>'s are the same or different when s represents 2 or more, respectively;

t represents 0 or 1; and

R<sup>5</sup> represents (1) a hydrogen atom, or (2) C1-8 alkyl, ~~(3) C2-8 alkenyl, or (4) C2-8 alkynyl,~~ or

a salt thereof.

**69. (withdrawn-currently amended)** A pharmaceutical composition comprising the compound according to claim ~~468~~, a salt thereof or a prodrug thereof and a pharmaceutically acceptable carrier.

**70. (withdrawn)** The pharmaceutical composition according to claim 69, which is an LPA receptor antagonist.

**71. (withdrawn)** The pharmaceutical composition according to claim 70, wherein the LPA receptor is EDG-2 receptor.

**72. (withdrawn)** The pharmaceutical composition according to claim 71, which is an agent for prevention and/or treatment for urinary system disease.

**73. (withdrawn)** The pharmaceutical composition according to claim 71, which is an agent for prevention and/or treatment for carcinoma-associated disease, proliferative disease, inflammation / immune system disease, disease caused by secretory dysfunction or brain-related disease.

**74. (withdrawn-currently amended)** A method for prevention and/or treatment of diseases referred from EDG-2, which comprises administering an effective amount of the compound according to claim ~~1~~68, a salt thereof or a prodrug thereof to a mammal.

**75. (withdrawn):** The method for prevention and/or treatment according to claim 74, wherein the disease referred from EDG-2 is urinary system disease.

**76. (withdrawn)** The method for prevention and/or treatment according to claim 74, wherein the disease referred from EDG-2 is carcinoma-associated disease, proliferative disease, inflammation / immune system disease, disease caused by secretory dysfunction or brain-related disease.

**Claims 77-79. (canceled).**

**80. (withdrawn-currently amended)** A pharmaceutical composition for prevention and/or treatment of urinary system disease comprising a combination of an LPA receptor antagonist containing the compound according to claim ~~1~~68, a salt thereof or a prodrug thereof as an active ingredient and one or two more agent(s) selected from other LPA receptor

antagonist,  $\alpha$ 1 blocking agent, anticholinergic agent,  $5\alpha$ -reductase inhibitor and/or anti-androgenic agent.